Insmed Incorporated — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; balance-sheet comparisons are to December 31, 2011. Insmed is a development-stage biopharmaceutical company focused on inhaled treatments for serious lung infections, principally ARIKACE for cystic fibrosis (CF) and nontuberculous mycobacteria (NTM).
Financial performance and position
| Metric | Q1 2012 | Q1 2011 or comparison |
|---|---|---|
| Revenue | $0 | $1.601 million |
| Research and development expense | $4.487 million | $5.760 million |
| General and administrative expense | $2.777 million | $3.256 million |
| Operating loss | $7.264 million | $7.415 million |
| Net loss | $6.845 million | $6.894 million |
| Net loss attributable to common stockholders | $6.845 million; $0.28 per share | $16.069 million; $0.85 per share |
| Net cash used in operating activities | $5.612 million | $5.109 million |
- Revenue was nil, so a revenue margin is not meaningful. Revenue in Q1 2011 included $1.351 million of expanded-access program income and $0.250 million of license fees.
- Cash, cash equivalents, short-term investments and certificate of deposit totaled $72.873 million at March 31, 2012, versus $78.357 million at year-end. Cash and cash equivalents were $22.043 million; short-term investments were $48.739 million.
- Total assets were $133.253 million and total liabilities were $5.119 million. Liabilities included $246,000 of current and long-term capital lease obligations; the filing reports no material conventional debt. Accumulated deficit was $301.018 million.
- Operating expenses totaled $7.264 million, down from $9.016 million. Comprehensive loss was $6.629 million, including a $216,000 unrealized investment gain.
Changes versus the prior comparable period
- Revenue fell by $1.601 million, primarily because IPLEX expanded-access cost-recovery revenue ended after inventory was depleted in December 2011, and no CISPLATIN license fee was received in Q1 2012.
- R&D expense decreased 22% to $4.487 million, mainly reflecting lower development and manufacturing costs while fewer trials were being initiated. G&A expense decreased by $479,000, primarily due to lower finance, legal and consulting costs related to the Transave merger and reverse stock split.
- Common-stockholder net loss improved by $9.224 million, but the comparison is affected by a $9.175 million noncash beneficial-conversion charge recorded in Q1 2011. Excluding that charge, net loss was relatively similar year over year. Weighted-average shares rose to 24.860 million from 18.814 million.
- Operating cash use increased to $5.612 million from $5.109 million. Investing activities provided $12.841 million, mainly from sales of short-term investments; financing activities used $34,000 for lease payments.
Outlook, development, risks and contingencies
- Management said available funds were expected to meet financial needs for fiscal 2012, but additional capital may be required in the future through licensing, debt or equity. The company expected continuing losses and no material revenues for at least several years.
- In January 2012, the FDA lifted the clinical hold on ARIKACE for NTM, permitting a U.S. Phase 2 trial; Insmed expected enrollment to begin mid-2012. The Phase 3 CF study CLEAR-108 was underway in Europe and planned for Canada. In May 2012, after quarter-end, the FDA lifted the U.S. CF clinical hold and agreed on a revised target population; protocol details remained under discussion.
- Management identified clinical, regulatory, manufacturing, enrollment, financing and commercialization uncertainties. A prior rat carcinogenicity study found a single lung tumor in two of 120 rats at the highest dose; the relevance to humans was unknown. A nine-month dog inhalation toxicity study began in April 2012.
- Insmed had two unresolved legal matters: Cacchillo v. Insmed, with three claims remaining and trial scheduled for January 2013, and a Transave stockholder appraisal action. The company said loss ranges could not be estimated for either matter and intended to defend them.
- A $1.4 million drug-supply contract was signed in January 2012 for the dog toxicity study. Management reported effective disclosure controls and no material changes to contractual obligations outside the ordinary course.
Important facts for investors to verify
- Progress, enrollment, endpoints and regulatory requirements for CLEAR-108 and the U.S. NTM Phase 2 trial, including any finalized U.S. CF protocol.
- Cash runway under the planned clinical program and the timing, amount and terms of any future financing.
- Whether ARIKACE clinical and toxicology results alter development plans or trigger impairment of the $58.2 million in-process research and development asset.
- Resolution and potential financial exposure from the Cacchillo and Transave appraisal proceedings, for which loss estimates were unavailable.
- Ongoing spending and the absence of recurring revenue following the end of IPLEX expanded-access cost recovery.